Neuroleptic malignant syndrome associated with clozapine monotherapy.
Neuroleptic malignant syndrome is thought to be a result of dopamine receptor blockade in the striatum. Clozapine has only weak affinity for dopamine type 1 and 2 receptors, and therefore it was thought this drug would not precipitate the syndrome. However, six cases of the syndrome have been reported in patients receiving clozapine monotherapy. A review of the pathoetiology of symptoms occurring in the syndrome is included.
Thornberg
S A
SA
Clinical Psychiatric Pharmacy Program, University of Texas Health Science Center at San Antonio 78284-6220.
Ereshefsky
L
L
D000328:Adult; D003024:Clozapine / Q000009:adverse effects* / Q000494:pharmacology; D015986:Confounding Factors, Epidemiologic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000209:etiology*; D011954:Receptors, Dopamine / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy; D012560:Schizophrenia, Catatonic / Q000188:drug therapy; D012563:Schizophrenia, Paranoid / Q000188:drug therapy
D011954:Receptors, Dopamine; D003024:Clozapine